Drug Trial Radar · NCT02643550
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Last checked: Nov 20, 2026Latest source record: May 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
143
Actual
Start
Dec 2015
Primary completion
Mar 28, 2023
Study completion Mar 28, 2023
Sponsor
- Lead sponsor
- Innate PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Dec 31, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1
Conditions
- Head and Neck Neoplasms
Interventions
MonalizumabBiological
CetuximabBiological
Anti-PD(L)1Biological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Dose Limiting Toxicities (DLT) in the dose escalation part of the studyTime frame: within 4 weeks after first administration
- Objective Response Rate for expansion cohortsTime frame: up to 12 months
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Moores Cancer Center
La Jolla, California
Stanford Cancer Center
Stanford, California
University of Chicago
Chicago, Illinois
University of Maryland, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Washington University School of Medicine
St Louis, Missouri
Icahn School of Medicine at Mount Sinaï
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Centre Jean Perrin
Clermont-Ferrand, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Hopital La Timone
Marseille, France
Institut Regional du Cancer de Montpellier
Montpellier, France
Centre Antoine Lacassagne
Nice, France
Centre Eugene Marquis
Rennes, France
ICO Rene Gauducheau
Saint-Herblain, France
Institut Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.